Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

48% chance
Polymarket
NOUVEAU
48% chance
Polymarket
NOUVEAU
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket tilts slightly toward "No" at 52% implied probability for Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7, reflecting prolonged evaluation without a full commercial commitment despite a December 2025 extension to October 2026. Peptron's ultrasonic spray-drying technology, designed for long-acting peptide injectables like GLP-1s, remains in joint R&D testing on Lilly's candidates, but skepticism stems from Lilly's June 2025 Camurus partnership for similar depot tech and recent pivots to oral obesity drugs such as Foundayo. This balance persists amid no fresh data readouts or announcements in the past month. Key catalysts include in vivo evaluation results or partnership updates ahead of the deadline, potentially swaying odds in Q3 earnings calls.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$8,097
Date de fin
7 oct. 2026
Marché ouvert
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket tilts slightly toward "No" at 52% implied probability for Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7, reflecting prolonged evaluation without a full commercial commitment despite a December 2025 extension to October 2026. Peptron's ultrasonic spray-drying technology, designed for long-acting peptide injectables like GLP-1s, remains in joint R&D testing on Lilly's candidates, but skepticism stems from Lilly's June 2025 Camurus partnership for similar depot tech and recent pivots to oral obesity drugs such as Foundayo. This balance persists amid no fresh data readouts or announcements in the past month. Key catalysts include in vivo evaluation results or partnership updates ahead of the deadline, potentially swaying odds in Q3 earnings calls.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$8,097
Date de fin
7 oct. 2026
Marché ouvert
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Méfiez-vous des liens externes.

Questions fréquentes

« Eli Lilly licenses Peptron’s SmartDepot by October 7? » est un marché de prédiction sur Polymarket où les traders achètent et vendent des parts « Oui » ou « Non » selon qu'ils estiment que cet événement se produira ou non. La probabilité actuelle selon la communauté est de 48% pour « Yes ». Par exemple, si « Oui » est coté à 48¢, le marché attribue collectivement une probabilité de 48% que cet événement se produise. Ces cotes changent en permanence à mesure que les traders réagissent aux nouveaux développements et informations. Les parts du résultat correct sont échangeables contre $1 chacune lors de la résolution du marché.

« Eli Lilly licenses Peptron’s SmartDepot by October 7? » est un marché nouvellement créé sur Polymarket, lancé le May 6, 2026. En tant que marché récent, c'est votre opportunité d'être parmi les premiers traders à définir les cotes et établir les premiers signaux de prix du marché. Vous pouvez également ajouter cette page à vos favoris pour suivre le volume et l'activité de trading au fil du temps.

Pour trader sur « Eli Lilly licenses Peptron’s SmartDepot by October 7? », choisissez simplement si vous pensez que la réponse est « Oui » ou « Non ». Chaque côté a un prix actuel qui reflète la probabilité implicite du marché. Entrez votre montant et cliquez sur « Trader ». Si vous achetez des parts « Oui » et que le résultat se résout comme « Oui », chaque part rapporte $1. S'il se résout comme « Non », vos parts « Oui » rapportent $0. Vous pouvez également vendre vos parts à tout moment avant la résolution pour sécuriser un gain ou limiter une perte.

La probabilité actuelle pour « Eli Lilly licenses Peptron’s SmartDepot by October 7? » est de 48% pour « Yes ». Cela signifie que la communauté Polymarket estime actuellement qu'il y a une probabilité de 48% que cet événement se produise. Ces cotes sont mises à jour en temps réel sur la base de transactions réelles, fournissant un signal continuellement actualisé de ce que le marché attend.

Les règles de résolution de « Eli Lilly licenses Peptron’s SmartDepot by October 7? » définissent exactement ce qui doit se produire pour que chaque résultat soit déclaré gagnant, y compris les sources de données officielles utilisées pour déterminer le résultat. Vous pouvez consulter les critères de résolution complets dans la section « Règles » sur cette page au-dessus des commentaires. Nous recommandons de lire attentivement les règles avant de trader, car elles précisent les conditions exactes, les cas particuliers et les sources.